An Automated Multiplexed Hepatotoxicity and CYP Induction Assay Using HepaRG Cells in 2D and 3D

Drug-induced liver injury (DILI) and drug–drug interactions (DDIs) are concerns when developing safe and efficacious compounds. We have developed an automated multiplex assay to detect hepatotoxicity (i.e., ATP depletion) and metabolism (i.e., cytochrome P450 1A [CYP1A] and cytochrome P450 3A4 [CYP3A4] enzyme activity) in two-dimensional (2D) and three-dimensional (3D) cell cultures. HepaRG cells were cultured in our proprietary micromold plates and produced spheroids. HepaRG cells, in 2D or 3D, expressed liver-specific proteins throughout the culture period, although 3D cultures consistently exhibited higher albumin secretion and CYP1A/CYP3A4 enzyme activity than 2D cultures. Once the spheroid hepatic quality was assessed, 2D and 3D HepaRGs were challenged to a panel of DILI- and CYP-inducing compounds for 7 days. The 3D HepaRG model had a 70% sensitivity to liver toxins at 7 days, while the 2D model had a 60% sensitivity. In both the 2D and 3D HepaRG models, 83% of compounds were predicted to be CYP inducers after 7 days of compound exposure. Combined, our results demonstrate that an automated multiplexed liver spheroid system is a promising cell-based method to evaluate DILI and DDI for early-stage drug discovery.

[1]  Sabine U. Vorrink,et al.  HepaRG cells and 3 D human hepatocyte spheroids as predictive in vitro systems for drug-induced liver injury , 2017 .

[2]  M. JakubekLorin,et al.  Hepatic Spheroids for Long-Term Toxicity Studies , 2016 .

[3]  Souren Mkrtchian,et al.  Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation , 2016, Hepatology.

[4]  Delilah F. G. Hendriks,et al.  Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability , 2016, Scientific Reports.

[5]  Volker M Lauschke,et al.  Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates. , 2016, Chemical research in toxicology.

[6]  W. Tong,et al.  Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles. , 2016, Chemico-biological interactions.

[7]  M. Ingelman-Sundberg,et al.  A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity , 2016, Archives of Toxicology.

[8]  M. Ingelman-Sundberg,et al.  Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease , 2016, Scientific Reports.

[9]  A. Zuppa,et al.  Epidemiology of Polypharmacy and Potential Drug–Drug Interactions Among Pediatric Patients in ICUs of U.S. Children’s Hospitals* , 2016, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[10]  F. Noor,et al.  Novel human hepatic organoid model enables testing of drug-induced liver fibrosis in vitro. , 2016, Biomaterials.

[11]  Takafumi Tomida,et al.  Multiparametric assay using HepaRG cells for predicting drug-induced liver injury. , 2015, Toxicology letters.

[12]  Y. Hori,et al.  3D spheroid cultures improve the metabolic gene expression profiles of HepaRG cells , 2015, Bioscience Reports.

[13]  A. Guillouzo,et al.  Impact of Inflammation on Chlorpromazine-Induced Cytotoxicity and Cholestatic Features in HepaRG Cells , 2014, Drug Metabolism and Disposition.

[14]  L. Stehno-Bittel,et al.  Assessment of re‐aggregated human pancreatic islets for secondary drug screening , 2014, British journal of pharmacology.

[15]  F. Noor,et al.  3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies. , 2014, Toxicology in vitro : an international journal published in association with BIBRA.

[16]  H. Arakawa,et al.  Evaluation of human hepatocytes cultured by three-dimensional spheroid systems for drug metabolism. , 2014, Drug metabolism and pharmacokinetics.

[17]  J. Talwalkar,et al.  Drug-induced liver injury. , 2014, Mayo Clinic proceedings.

[18]  Matthew H Bridgland-Taylor,et al.  A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.

[19]  Adam S. Hayward,et al.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME , 2013, Archives of Toxicology.

[20]  S. Olafsson,et al.  Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. , 2013, Gastroenterology.

[21]  Elmar Heinzle,et al.  3D organotypic cultures of human HepaRG cells: a tool for in vitro toxicity studies. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  M. Milburn,et al.  Metabolomic signatures in lipid-loaded HepaRGs reveal pathways involved in steatotic progression , 2013, Obesity.

[23]  Kate Lawrenson,et al.  A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro , 2013, Laboratory Investigation.

[24]  L. Stehno-Bittel,et al.  Engineering islets for improved performance by optimized reaggregation in a micromold. , 2013, Tissue engineering. Part A.

[25]  N. Kaplowitz.  Drug-Induced Liver Injury: Introduction and Overview , 2013 .

[26]  Ivan Rusyn,et al.  In vitro models for liver toxicity testing. , 2013, Toxicology research.

[27]  S. Takayama,et al.  Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[28]  J. Kelm,et al.  Multi-cell type human liver microtissues for hepatotoxicity testing , 2012, Archives of Toxicology.

[29]  S. Iturria,et al.  HTS Assay Validation , 2012 .

[30]  Patrick Y. Muller,et al.  The determination and interpretation of the therapeutic index in drug development , 2012, Nature Reviews Drug Discovery.

[31]  André Guillouzo,et al.  An adaptation of the human HepaRG cells to the in vitro micronucleus assay. , 2012, Mutagenesis.

[32]  Maria Vinci,et al.  Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation , 2012, BMC Biology.

[33]  P. Banks,et al.  Automated Triplexed Hepatocyte-Based Viability and CYP1A and -3A Induction Assays , 2011, Journal of biomolecular screening.

[34]  P B Watkins,et al.  Drug Safety Sciences and the Bottleneck in Drug Development , 2011, Clinical pharmacology and therapeutics.

[35]  A. Guillouzo,et al.  Induction of vesicular steatosis by amiodarone and tetracycline is associated with up‐regulation of lipogenic genes in heparg cells , 2011, Hepatology.

[36]  Hartmut Jaeschke,et al.  HepaRG cells: A human model to study mechanisms of acetaminophen hepatotoxicity , 2011, Hepatology.

[37]  J. Mckim.  Building a Tiered Approach to In Vitro Predictive Toxicity Screening: A Focus on Assays with In Vivo Relevance , 2010, Combinatorial chemistry & high throughput screening.

[38]  Jane R Kenny,et al.  Evaluation of Multiple in Vitro Systems for Assessment of CYP3A4 Induction in Drug Discovery: Human Hepatocytes, Pregnane X Receptor Reporter Gene, and Fa2N-4 and HepaRG Cells , 2009, Drug Metabolism and Disposition.

[39]  L. Tremaine,et al.  PREDICTION OF DRUG-DRUG INTERACTIONS FROM IN VITRO INDUCTION DATA , 2008, Drug Metabolism and Disposition.

[40]  F. Pampaloni,et al.  The third dimension bridges the gap between cell culture and live tissue , 2007, Nature Reviews Molecular Cell Biology.

[41]  André Guillouzo,et al.  The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. , 2007, Chemico-biological interactions.

[42]  Hayley S. Brown,et al.  Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies , 2007, Drug metabolism reviews.

[43]  P. Bernardi,et al.  High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening , 2006, Archives of Toxicology.

[44]  André Guillouzo,et al.  EXPRESSION OF CYTOCHROMES P450, CONJUGATING ENZYMES AND NUCLEAR RECEPTORS IN HUMAN HEPATOMA HepaRG CELLS , 2006, Drug Metabolism and Disposition.

[45]  B. Andrews,et al.  New Technologies and Screening Strategies for Hepatotoxicity: Use of In Vitro Models , 2005, Toxicologic pathology.

[46]  P. Hillon,et al.  Incidence of drug‐induced hepatic injuries: A French population‐based study , 2002, Hepatology.

[47]  E L LeCluyse,et al.  Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.